Electric Field Stimulation for Epilepsy (EE-DES-TIEF Trial)

N/A

Waitlist Available

Research Sponsored by University of California, Davis

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients undergoing invasive intracranial EEG studies

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from enrollment until the end of the admission for each patient (the admission is typically 7-14 days in duration).

Awards & highlights

No Placebo-Only Group

Summary

This trial explores using a new type of electric field stimulation called TIEFS to treat epilepsy. The study looks at how TIEFS affects epilepsy biomarkers in patients with medial temporal lobe epilepsy.

Who is the study for?

This clinical trial is for individuals with medial temporal lobe epilepsy. Specific details about who can join are not provided, but typically participants must meet certain health criteria and may need to have a specific form of the condition being studied.

What is being tested?

The study is examining temporally-interfering electric field stimulation (TIEFS) as a treatment for epilepsy. It looks at how TIEFS affects epilepsy biomarkers and brain activity in patients, using both within-subject and between-subjects comparisons.

What are the potential side effects?

Potential side effects are not detailed here, but TIEFS could possibly cause discomfort or changes in brain function given it involves electrical stimulation of the brain.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am undergoing a brain EEG study that involves inserting electrodes.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from enrollment until the end of the admission for each patient (the admission is typically 7-14 days in duration).

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from enrollment until the end of the admission for each patient (the admission is typically 7-14 days in duration).

This trial's timeline: 3 weeks for screening, Varies for treatment, and from enrollment until the end of the admission for each patient (the admission is typically 7-14 days in duration). for reporting.